Preoperative levels of matrix metalloproteinase-7 and -9 and tissue inhibitor of matrix metalloproteinase-1 relation to pathologic parameters in bladder carcinoma patients
| dc.contributor.author | Gunes M. | |
| dc.contributor.author | Kemik A.S. | |
| dc.contributor.author | Pirincci N. | |
| dc.contributor.author | Gecit I. | |
| dc.contributor.author | Taken K. | |
| dc.contributor.author | Yuksel M.B. | |
| dc.contributor.author | Kaba M. | |
| dc.contributor.author | Eryilmaz R. | |
| dc.date.accessioned | 2025-04-10T11:14:38Z | |
| dc.date.available | 2025-04-10T11:14:38Z | |
| dc.date.issued | 2013 | |
| dc.description.abstract | Our aim was to test the hypothesis that preoperative serum levels of matrix metalloproteinase-7 (MMP-7) and -9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) levels correlate with pathological features. Serum levels of MMP-7, and MMP-9 and TIMP-1 were determined in 90 bladder cancer patients and 40 healthy controls using an enzyme linked immunosorbent assay. Preoperative serum MMP-7 and MMP-9 levels were significantly higher in cancer patients than control groups (p<0.001). In contast, serum TIMP-1 levels were lower (p<0.001). Alteration in MMP-7, and MMP-9, and TIMP-1 production may contribute to tumor angiogenesis and be associated with clinic-pathological features. | |
| dc.identifier.DOI-ID | 10.7314/APJCP.2013.14.2.873 | |
| dc.identifier.uri | http://hdl.handle.net/20.500.14701/50393 | |
| dc.publisher | Asian Pacific Organization for Cancer Prevention | |
| dc.title | Preoperative levels of matrix metalloproteinase-7 and -9 and tissue inhibitor of matrix metalloproteinase-1 relation to pathologic parameters in bladder carcinoma patients | |
| dc.type | Article |